Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies takeda.com ↗
2023-12-21
Takeda
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies takeda.com ↗
2022-12-19
Takeda
Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint takeda.com ↗
2022-11-11
Takeda
European Commission (EC) Approves LIVTENCITY TM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies takeda.com ↗
2022-09-16
Takeda
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies takeda.com ↗
2022-04-22
Takeda
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay takeda.com ↗
2021-12-08
Takeda
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance) takeda.com ↗
2021-11-23
Takeda
Takeda’s LIVTENCITY TM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies takeda.com ↗
2021-10-07
Takeda
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance takeda.com ↗
2021-06-07
Takeda
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance) takeda.com ↗
2021-05-21
Takeda
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment takeda.com ↗
2021-03-15
Takeda
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance) takeda.com ↗
2021-02-12
Takeda
Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease takeda.com ↗
2020-12-04
Takeda
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint takeda.com ↗
2019-09-25
Takeda
New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection takeda.com ↗
2018-01-04
Takeda
Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients takeda.com ↗
2016-10-27
Takeda
Results from Shire's Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant takeda.com ↗
Evidence & citations 10 cited values
Every value below carries the sentence it was read from.
21 sources stand behind the page.
Field
Value
Cited text
Known as
maribavir
ClinicalTrials.gov intervention name — accepted as the source's own labelNCT00411645 ↗17
“multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding” NCT00002373 ↗
Known as
BW-1263W94
ChEMBL registry synonym — accepted as the source's own labelCHEMBL515408 ↗
Known as
GW-257406X
ChEMBL registry synonym — accepted as the source's own labelCHEMBL515408 ↗
Known as
Livtencity
ChEMBL registry synonym — accepted as the source's own labelCHEMBL515408 ↗
Known as
MBV
“Viral mutations conferring resistance against nucleotide and pyrophosphate analogs as well as maribavir (MBV) have evolved sequentially.” PMID 23870704 ↗Jul 2013
Known as
SHP620
“Study of SHP620 (Maribavir) in Healthy Adults” NCT02775240 ↗
Action
Inhibit
“maribavir, an inhibitor of the cytomegalovirus UL97 protein” PMID 23870704 ↗Jul 2013
Modality
Small molecule
“Maribavir is an oral benzimidazole riboside” PMID 38071422 ↗Jan 2024